1
Andreas Huth, Dieter Seidelmann, Karl Heinz Thierauch, Guido Bold, Paul William Manley, Pascal Furet, Jeanette Marjorie Wood, Jürgen Mestan, Jose Brüggen, Stefano Ferrari, Martin Krüger, Eckhard Ottow, Andreas Menrad, Michael Schirner: Anthranilic acid amides and the use thereof as medicaments. Schering, Novartis, Millen White Zelano & Branigan P C, October 17, 2006: US07122547 (36 worldwide citation)

The invention relates to anthranilic acid amides and the use thereof as medicaments for the treatment of diseases that are triggered by persistent angiogenesis, in addition to intermediate products in the production of anthranilic acid amides.


2

3
Karl Heinz Altmann, Guido Bold, Pascal Furet, Paul William Manley, Jeanette Marjorie Wood, Stefano Ferrari, Francesco Hofmann, Jürgen Mestan, Andreas Huth, Martin Krüger, Dieter Seidelmann, Andreas Menrad, Martin Haberey, Karl Heinz Thierauch: VEGF receptor tyrosine kinase inhibitors. Novartis, Schering Aktiengesellschaft, Lydia T McNally, George R Dohmann, April 12, 2005: US06878720 (22 worldwide citation)

Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R1 is aryl; R2 is a bicyclic heteroaryl group comprising o ...


4
Karl Heinz Altmann, Guido Bold, Pascal Furet, Paul William Manley, Jeanette Marjorie Wood, Stefano Ferrari, Francesco Hofmann, Jürgen Mestan, Andreas Huth, Martin Krüger, Dieter Seidelmann, Andreas Menrad, Martin Haberey, Karl Heinz Thierauch: N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF. Novartis, Schering Aktiengesellschaft, Lydia T McNally, February 21, 2006: US07002022 (10 worldwide citation)

Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R2 is aryl; R2 is a mono- or bicyclic heteroaryl group com ...


5
Leila Alland, Doriano Fabbro, Jürgen Mestan, Paul W Manley: Pyrimidylaminobenzamide derivatives for systemic mastocytosis. Novartis, Stephen Johnson, March 18, 2014: US08673930

The present invention relates to the use of pyrimidylaminobenzamide derivatives for the preparation of a drug for the treatment of systemic mastocytosis.


6
Paul W Manley, Jürgen Mestan, Doriano Fabbro: Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome. Novartis, Matthew Mulkeen, February 23, 2010: US07666874

The present invention relates to the use of pyrimidylaminobenzamide derivatives for the preparation of a drug for the treatment of FIP1L1-PDGFRα-induced or TEL-PDGFRβ-induced myeloproliferative diseases, especially for the curative and/or prophylactic treatment of hypereosinophilic syndrome and hype ...


7
Leila Alland, Doriano Fabbro, Jürgen Mestan, Paul W Manley: Pyrimidylaminobenzamide derivatives for systemic mastocytosis. Novartis, Corporate Intellectual Property, August 19, 2010: US20100210673-A1

The present invention relates to the use of pyrimidylaminobenzamide derivatives for the preparation of a drug for the treatment of systemic mastocytosis.